Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Theravance Biopharma Inc TBPH

Healthcare Biotechnology
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic... see more

Recent & Breaking News (NDAQ:TBPH)

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

PR Newswire November 20, 2025

Theravance Biopharma to Participate in Upcoming Investor Conferences

PR Newswire November 19, 2025

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire November 10, 2025

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

PR Newswire October 29, 2025

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

PR Newswire October 27, 2025

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

Business Wire October 16, 2025

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

PR Newswire October 14, 2025

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

PR Newswire September 2, 2025

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

PR Newswire August 25, 2025

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire August 12, 2025

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

PR Newswire July 28, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference

PR Newswire July 23, 2025

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

PR Newswire June 26, 2025

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

PR Newswire June 2, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference

PR Newswire May 13, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

PR Newswire May 9, 2025

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire May 8, 2025

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

PR Newswire April 28, 2025

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

PR Newswire April 24, 2025

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

PR Newswire April 7, 2025

Podcasts